Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: April 03, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT04209465

BDTX-189 in Metastatic Breast Cancer That Tests Positive for Certain Markers (Mutations)

MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies Scientific Title

Purpose
To study the safety, effects (good and bad), best dose, and anti-cancer activity of the experimental targeted therapy BDTX-189.
Who is this for?
People with metastatic (stage IV) breast cancer whose tumor tests positive for one of several markers (mutations) listed below.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BDTX-189, by mouth, daily, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BDTX-189 targets certain mutations in the ErbB group of receptor tyrosine kinases. </li> <li class="seamTextUnorderedListItem">To be eligible for this study, your tumor must test positive for one of these ErbB markers (muations): allosteric HER2 or HER3, EGFR or HER2 exon 20 insertion, HER2 positive (HER2+), EGFR exon 19 deletion, or L858R. </li> <li class="seamTextUnorderedListItem">People with other types of metastatic breast cancer are also being enrolled in this study.</li> <li class="seamTextUnorderedListItem">Targets or mutations: allosteric HER2 or HER3, EGFR or HER2 exon 20 insertion, HER2 positive, EGFR exon 19 deletion, or L858R</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04209465' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.blackdiamondtherapeutics.com/pipeline/bdtx-189/' target='_blank'>Drug Company Information Page: BDTX-189</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies' target='_blank'>Breastcancer.org: Targeted Therapies</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/25435079' target='_blank'>Article Abstract: Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer.</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.frontiersin.org/articles/10.3389/fonc.2013.00086/full' target='_blank'>Journal Article: Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/797057' target='_blank'>NCI Dictionary of Cancer Terms: Basket Trial</a> </li></ul>
See more